A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection

BACKGROUND: Schistosomiasis is responsible for a considerable global disease burden. This work aimed to improve the therapeutic outcome of the only available antischistosomal drug worldwide, praziquantel (PZQ), by incorporating it into a novel carrier, “solid lipid nanoparticles (SLNs)”, to enhance...

Descripción completa

Detalles Bibliográficos
Autores principales: Radwan, Amr, El-Lakkany, Naglaa M., William, Samia, El-Feky, Gina S., Al-Shorbagy, Muhammad Y., Saleh, Samira, Botros, Sanaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580642/
https://www.ncbi.nlm.nih.gov/pubmed/31208446
http://dx.doi.org/10.1186/s13071-019-3563-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580642/
https://www.ncbi.nlm.nih.gov/pubmed/31208446
http://dx.doi.org/10.1186/s13071-019-3563-z

Ejemplares similares